



United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Dox 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/001,489	10/23/2001	Abdul Malik	0152.00420	3233
7	7590 07/21/2003		*	
Gregory A. Nelson AKERMAN SENTERFITT 222 Lakeview Ave Suite 400		•, -,	. EXAMINER	
			THERKORN, ERNEST G	
P.O. Box 3188 West Palm Beach, FL 33402-3188		•	ART UNIT	PAPER NUMBER
	,		1723	15
			DATE MAILED: 07/21/2003	

Please find below and/or attached an Office communication concerning this application or proceeding.

U.S. Patent and Trademark Office PTO-326 (Rev. 04-01) Application/Control Number: 10/001,489

Art Unit: 1723

Newly submitted claims 12-19, directed to an invention that is independent or distinct from the invention originally claimed for the following reasons:

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- Claims 1-11, drawn to a method of preconcentrating analytes, classified in class 210, subclass 635.
- II. Claims 12-15, drawn to a microextraction device, classified in class 210, subclass 198.2.
- III. Claims 16-19, drawn to a method of forming a microextraction device, classified in class 210, subclass 656.

The inventions are distinct, each from the other because:

Inventions I and II are related as process and apparatus for its practice. The inventions are distinct if it can be shown that either: (1) the process as claimed can be practiced by another materially different apparatus or by hand, or (2) the apparatus as claimed can be used to practice another and materially different process. (MPEP § 806.05(e)). In this case, the apparatus as claimed could be used to practice another and materially different process. For example, the apparatus could be used as a chemical reactor or a biochemical reactor in a chemical or biochemical reaction process.

Inventions I and III are not related because they are drawn to different methods with different purposes and different steps.

Inventions II and III are related as process of making and product made. The inventions are distinct if either or both of the following can be shown: (1) that the

process as claimed can be used to make other and materially different product or (2) that the product as claimed can be made by another and materially different process (MPEP § 806.05(f)). In the instant case, the product as claimed could be made by another and materially different process. For example, the hollow capillary could be formed in situ around the sol gel extraction medium.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification, restriction for examination purposes as indicated is proper.

Since applicant has received an action on the merits for the originally presented invention, this invention has been constructively elected by original presentation for prosecution on the merits. Accordingly, claims 12-19 are withdrawn from consideration as being directed to a non-elected invention. See 37 CFR 1.142(b) and MPEP § 821.03.

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claims 1-11 are rejected under 35 U.S.C. 103(a) as being unpatentable over Kataoka (Anal. Chem. October 1, 1999, 71 4237-4244) in view of Chong (Anal. Chem. 1997, 69, 3889-3898) and either Wang (Anal. Chem. 1997, 69, 4566-4576) or Malik

Art Unit: 1723

(Advanced Sol-gel Column Technology for Condensed-phase Microseparations, 1997, page 54). At best, the claims differ from Kataoka (Anal. Chem. October 1, 1999, 71 4237-4244) in reciting use of sol gel. Chong (Anal. Chem. 1997, 69, 3889-3898) discloses sol gel chemistry allows low costs, has the unique ability to achieve molecular uniformity, and has a strong adhesion of the coating to the substrate. Wang (Anal. Chem. 1997, 69, 4566-4576) (Abstract) discloses that sol gel coated columns provide efficient separation for analytes from a wide polarity range and because of direct chemical bonding to fused silica substrates sol-gel coatings possess significantly higher thermal stability than conventional coatings. Malik (Advanced Sol-gel Column Technology for Condensed-phase Microseparations, 1997, page 54) discloses the advanced features of sol-gel chemistry can be effectively applied in an open column and chemical bonding of the coating or the monolithic bed to the column walls provides enhanced operational stability to the sol-gel columns. It would have been obvious to use sol gel in Kataoka (Anal. Chem. October 1, 1999, 71 4237-4244) because Chong (Anal. Chem. 1997, 69, 3889-3898) discloses sol gel chemistry allows low costs, has the unique ability to achieve molecular uniformity, and has a strong adhesion of the coating to the substrate and either because Wang (Anal. Chem. 1997, 69, 4566-4576) (Abstract) discloses that sol gel coated columns provide efficient separation for analytes from a wide polarity range and because of direct chemical bonding to fused silica substrates sol-gel coatings possess significantly higher thermal stability than conventional coatings or because Malik (Advanced Sol-gel Column Technology for Condensed-phase Microseparations, 1997, page 54) discloses the advanced features

Application/Control Number: 10/001,489

Art Unit: 1723

of sol-gel chemistry can be effectively applied in an open column and chemical bonding of the coating or the monolithic bed to the column walls provides enhanced operational stability to the sol-gel columns.

Claim 4 is rejected under 35 U.S.C. 103(a) as being unpatentable over Kataoka (Anal. Chem. October 1, 1999, 71 4237-4244) in view of Chong (Anal. Chem. 1997, 69, 3889-3898) and either Wang (Anal. Chem. 1997, 69, 4566-4576) or Malik (Advanced Sol-gel Column Technology for Condensed-phase Microseparations, 1997, page 54) as applied to claims 1-11 above, and further in view of either Malik (Advanced Sol-gel Column Technology for Condensed-phase Microseparations, 1997, page 54) or Nakanishi (U.S. Patent No. 5,624,875). At best, the claim differs from Kataoka (Anal. Chem. October 1, 1999, 71 4237-4244) in view of Chong (Anal. Chem. 1997, 69, 3889-3898) and either Wang (Anal. Chem. 1997, 69, 4566-4576) or Malik (Advanced Sol-gel Column Technology for Condensed-phase Microseparations, 1997, page 54) in reciting use of a monolith. Malik (Advanced Sol-gel Column Technology for Condensed-phase Microseparations, 1997, page 54) discloses that open tubular columns and monolithic columns are interchangeable alternatives to apply the advanced features of sol gel chemistry. Nakanishi (U.S. Patent No. 5,624,875) (column 4, lines 25-27 and column 6, lines 39-46) discloses that sol gel monolithic columns have very low flow resistance. It would have been obvious to use a monolith in Kataoka (Anal. Chem. October 1, 1999, 71 4237-4244) in view of Chong (Anal. Chem. 1997, 69, 3889-3898) and either Wang (Anal. Chem. 1997, 69, 4566-4576) or Malik (Advanced Sol-gel Column Technology for Condensed-phase Microseparations, 1997, page 54) either because Malik (Advanced

Application/Control Number: 10/001,489

Art Unit: 1723

Sol-gel Column Technology for Condensed-phase Microseparations, 1997, page 54) discloses that open tubular columns and monolithic columns are interchangeable alternatives to apply the advanced features of sol gel chemistry or because Nakanishi (U.S. Patent No. 5,624,875) (column 4, lines 25-27 and column 6, lines 39-46) discloses that sol gel monolithic columns have very low flow resistance.

The remarks urge that Kataoka (Anal. Chem. October 1, 1999, 71 4237-4244) is directed to physically bonded capillaries. However, this appears to be a mere allegation unsupported by fact. Kataoka (Anal. Chem. October 1, 1999, 71 4237-4244) would appear to be silent on the issue of chemical bonding.

The remarks urge patentability based upon chemical bonding. However, Wang (Anal. Chem. 1997, 69, 4566-4576) (Abstract) discloses because of direct chemical bonding to fused silica substrates sol-gel coatings possess significantly higher thermal stability than conventional coatings. In addition, Malik (Advanced Sol-gel Column Technology for Condensed-phase Microseparations, 1997, page 54) discloses chemical bonding of the coating or the monolithic bed to the column walls provides enhanced operational stability to the sol-gel columns.

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the

Page 7

shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Any inquiry concerning this communication should be directed to E. Therkorn at

telephone number (703) 308-0362.

Ernest G. Therkorn Primary Examiner Art Unit 1723

EGT/12 July 16, 2003